Clinical Trial Update: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 20-valent pneumococcal conjugate vaccine (pneumococcal conjugate vaccine, 20-valent)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-04-21